Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Topics Sessions Videos Previous meetings

Posters by Session

Select Session

Thumbnail for Infectious Complications in Patients With Mantle Cell Lymphoma Treated With CAR-T Therapy: A Real-World TriNetX Analysis

MCL - 668

Infectious Complications in Patients With Mantle Cell Lymphoma Treated With CAR-T Therapy: A Real-World TriNetX Analysis

Anushree Venkatesh Murthy

Poster Presenter: Anushree Venkatesh Murthy

Thumbnail for Descriptive Characteristics of NOTCH1-Mutated Mantle Cell Lymphoma

MCL - 814

Descriptive Characteristics of NOTCH1-Mutated Mantle Cell Lymphoma

Ayda Soltanian

Poster Presenter: Ayda Soltanian

$Thumbnail for Real-World Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma$

Previous 1...90 91 92 93 94 95 96...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

MCL - 906

Real-World Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma

Sally Jones*

Poster Presenter: Sally Jones*

Thumbnail for Targeted Therapy Era and the Reclassification of Mantle Cell Lymphoma From Underlying to Contributing Cause of Death: A 22-Year National Multiple-Cause-of-Death Analysis

MCL - 932

Targeted Therapy Era and the Reclassification of Mantle Cell Lymphoma From Underlying to Contributing Cause of Death: A 22-Year National Multiple-Cause-of-Death Analysis

Aroog Khaliq

Poster Presenter: Aroog Khaliq

Thumbnail for Artificial Intelligence in the Diagnosis of Severe Aplastic Anemia: A Systematic Review of Emerging Diagnostic Models

MDS - 098

Artificial Intelligence in the Diagnosis of Severe Aplastic Anemia: A Systematic Review of Emerging Diagnostic Models

Eman M Nagiub

Poster Presenter: Eman M Nagiub

Thumbnail for Rising Mortality and Persistent Disparities in Hematologic Malignancies and Aplastic Anemia Among U.S. Adults: A Population-Based Analysis, 1999-2025

MDS - 1007

Rising Mortality and Persistent Disparities in Hematologic Malignancies and Aplastic Anemia Among U.S. Adults: A Population-Based Analysis, 1999-2025

Muhammad Jawad

Poster Presenter: Muhammad Jawad

Thumbnail for Cooperative Effects of U2AF1-S34 and BCOR Mutations in Myeloid Neoplasms

MDS - 1034

Cooperative Effects of U2AF1-S34 and BCOR Mutations in Myeloid Neoplasms

Akram Abushamma

Poster Presenter: Akram Abushamma

Thumbnail for Spliceosome-Targeting Therapies in SF3B1-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Clinical Efficacy and Safety

MDS - 1049

Spliceosome-Targeting Therapies in SF3B1-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Clinical Efficacy and Safety

Ashil Mulllath

Poster Presenter: Ashil Mulllath

Thumbnail for A Phase 2 Open-Label Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's-Choice Thrombopoietin Receptor Agonist in Patients With Primary Immune Thrombocytopenia: VAY2EXPLORE Study Design

MDS - 1074

A Phase 2 Open-Label Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's-Choice Thrombopoietin Receptor Agonist in Patients With Primary Immune Thrombocytopenia: VAY2EXPLORE Study Design

Mary Lisha Paul

Poster Presenter: Mary Lisha Paul

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors